Immuntep, Collaborates with Merck KGaA and Pfizer for Clinical Trial and Supply Agreement for Eftilagimod Alpha with Avelumab

 Immuntep, Collaborates with Merck KGaA and Pfizer for Clinical Trial and Supply Agreement for Eftilagimod Alpha with Avelumab

Immuntep, Collaborates with Merck KGaA and Pfizer for Clinical Trial and Supply Agreement for Eftilagimod Alpha with Avelumab

Shots:

  • The companies jointly enter into P-I trial evaluating the clinical benefits, combining immune stimulator, Immuntep’s eftilagimod alpha (“efti” or “IMP321”), with Merck and Pfizer’s avelumab. Alliances will jointly develop and commercialize avelumab
  • The Institute of Clinical Cancer Research, will sponsor the trial, conducted & involved under ongoing INSIGHT clinical study evaluating P-II dose of efti when combined with avelumab in patients with advanced solid malignancies, assessing its safety, efficacy and tolerability
  • Avelumab is a human anti-programmed death ligand-1 (PD-L1) Ab currently being evaluated in JAVELIN clinical development program with seven P-III trials. Eftilagimod is a LAG-3Ig fusion protein currently in P-IIb chemoimmunotherapy for metastatic breast cancer and in P-I combination therapy trial for metastatic melanoma termed TACTI-mel

Click here to read full press release/ article | Ref: Immuntep | Image:  Wikimedia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post